Clinical Trials

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07572929 2026-05-07

PREeMPT

MyeloidOther hematologic neoplasm

450 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07514715 2026-04-13

RT4

129 enrolled

Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

10 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 1/2 Not yet recruiting

69 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07483476 2026-03-19

CIRCALL

LymphoidOther hematologic neoplasm

205 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454486 2026-03-06

TRACE-BTC

300 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

LymphoidOther hematologic neoplasm

330 enrolled

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

100 enrolled

Colonic Neoplasms, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

276 enrolled

Recurrence, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

50 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

LymphoidOther hematologic neoplasm

23 enrolled

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07269067 2025-12-08

DUALFLOW

60 enrolled

Phase 2/3 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

87 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

90 enrolled

Neoplasm, Residual

NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

200 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT06941987 2025-04-24

Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer

66 enrolled

Neoplasm, Residual

NCT06763302 2025-01-08

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

1,220 enrolled

Neoplasm, Residual

NCT06449846 2024-06-10

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

152 enrolled

Carcinoma, Hepatocellular, Recurrence, Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

225 enrolled

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

226 enrolled

Thoracic

Lung Neoplasms, Neoplasm, Residual

NCT06287723 2024-03-01

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

30 enrolled

Phase 3 Not yet recruiting

Colorectal Neoplasms, Neoplasm, Residual

NCT05427669 2022-10-07

AFFORD

340 enrolled